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Dimethylglycine dehydrogenase (DMGDH) (E.C. number 1.5.99.2) is a mitochondrial matrix enzyme involved in
the metabolism of choline, converting dimethylglycine to sarcosine. Sarcosine is then transformed to glycine by
sarcosine dehydrogenase (E.C. number 1.5.99.1). Both enzymes use flavin adenine dinucleotide and folate in their
reaction mechanisms. We have identified a 38-year-old man who has a lifelong condition of fishlike body odor and
chronic muscle fatigue, accompanied by elevated levels of the muscle form of creatine kinase in serum. Biochemical
analysis of the patient’s serum and urine, using 1H-nuclear magnetic resonance NMR spectroscopy, revealed that
his levels of dimethylglycine were much higher than control values. The cDNA and the genomic DNA for human
DMGDH (hDMGDH) were then cloned, and a homozygous ArG substitution (326 ArG) was identified in both
the cDNA and genomic DNA of the patient. This mutation changes a His to an Arg (H109R). Expression analysis
of the mutant cDNA indicates that this mutation inactivates the enzyme. We therefore confirm that the patient
described here represents the first reported case of a new inborn error of metabolism, DMGDH deficiency.
Introduction
The catabolism of choline in mitochondria is a cyclical
process, involving the formation of betaine, dimethylgly-
cine, sarcosine, glycine, and serine, with the ultimate re-
generation of choline (fig. 1). The interconversion of these
species involves the transfer of “1-carbon” units at the
level of active formaldehyde (Mackenzie andAbeles 1956;
Mackenzie and Frisell 1958;Wittwer andWagner 1981a).
One methyl group is removed from dimethylglycine by
dimethylglycine dehydrogenase (DMGDH) to form the
modified amino acid sarcosine. A second methyl group is
removed from sarcosine by sarcosine dehydrogenase
(SDH) to form glycine (Frisell and Mackenzie 1962;
Lang et al. 1994; Wittwer and Wagner 1981a, 1981b).
Both enzymes are associated with a folate derivative as
a coenzyme (Wittwer and Wagner 1980, 1981a, 1981b;
Steenkamp and Husain 1982; Wagner et al. 1984). In
each reaction, one methyl group is donated to one
tetrahydrofolate (H4PteGlu) molecule, forming 5,10-
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methylenetetrahydrofolate (5,10-CH2-H4PteGlu), which
is termed “active formaldehyde.” This activated form
of formaldehyde, in turn, is able to donate a methyl
group in the formation of serine from glycine via se-
rine hydroxymethyltransferase. In addition, 5,10-CH2-
H4PteGlu can be used in the conversion of deoxyuridine
monophosphate to deoxythimidine monophosphate; it
can be reduced to 5-methyltetrahydrofolate (5-CH3-
H4PteGlu) for synthesis of methionine from homocy-
steine via homocysteine methyltransferase (methionine
synthase); and it may be oxidized to 10-formyltetrahy-
drofolate (10-CHO-H4PteGlu) for purine synthesis. In
the case of DMGDH and SDH, the preferred folate de-
rivative in the reaction is H4PteGlu5, although other de-
rivatives may be used (Strong et al. 1989; Wittwer and
Wagner 1981b). The DMGDH and SDH reactions may
proceed in the absence of folate if folate becomes dis-
associated from the enzymes or if the person has a folate
deficiency. However, the end products of the reactions
when the folate cofactor is missing are formaldehyde
and formate (Steenkamp and Husain 1982; Wittwer and
Wagner 1981a). Both SDH and DMGDH have been
shown to be major folate-binding proteins (Wittwer and
Wagner 1980, 1981a, and 1981b).
In addition to their folate cofactor, both DMGDH
and SDH have a covalently bound flavin adenine di-
nucleotide (FAD) (Wittwer and Wagner 1981a; Cook
et al. 1984). Flavin peptides with a FAD covalently at-
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Figure 1 Metabolic pathways involving choline. The key relationships between glycine, serine, dimethylglycine, and sarcosine are indicated,
as are the various fates of “active formaldehyde” (adapted from Wittwer and Wagner 1981a).
tached have been isolated from both rat DMGDH
(rDMGDH) and rat SDH (rSDH) (Cook et al. 1984 and
1985). The covalent attachment occurs via a His(N3)/
flavin (8a carbon) linkage at H84 in rDMGDH, and
the recent cloning of rSDH cDNA shows that covalent
FAD attachment occurs at H109 in rSDH (Cook et al.
1984; Lang et al. 1991; Bergeron et al. 1998). Although
the exact reaction mechanism for these two enzymes is
unknown, electrons are subsequently transferred from
this FAD to electron-transferring flavoprotein (ETF),
then to ETF dehydrogenase, and finally to the mito-
chondrial electron-transport system (Hoskins and Mac-
kenzie 1961).
A deficiency of SDH was first identified in a 10-mo-
old male infant, who died soon after reaching the age
of 1 year. He had elevated levels of sarcosine in his urine
and serum (Gerritsen and Waisman 1966). A total of
20 patients who are thought to have SDH deficiency
have been described in the literature (Scott 1995). Clin-
ical symptoms have been difficult to correlate with sar-
cosinemia/sarcosinuria, and some researchers believe
that the diagnosis of sarcosinemia/sarcosinuria is un-
related to any clinical symptoms (Gerritsen 1972; Scott
1995). All patients, however, have been characterized
by elevated levels of sarcosine in urine and/or serum.
Dimethylglycine is normally found in urine and serum
at very low levels, and elevated levels of dimethylglycine
are sometimes found to be secondary to another dis-
order, such as folate or cobalamin deficiency (Porter et
al. 1985; Allen et al. 1993; Dudman et al. 1993). We
recently identified a patient who had elevated levels of
dimethylglycine in serum and urine. The patient was
identified through 1H-nuclear magnetic resonance
(NMR) studies of serum and urine that revealed di-
methylglycine levels much higher than normal values
(reported in detail by Moolenaar et al. [1999]). r-
DMGDH cDNA has been used to clone the cDNA
for human DMGDH (hDMGDH) from expressed-
sequence tag (EST) databases. A homozygous muta-
tion was identified in DMGDH cDNA and genomic
DNA from this patient (GenBank accession number
AF111858). Studies of recombinant mutant protein
show that the mutation inactivates the enzyme.
Patient and Methods
hDMGDH cDNA Cloning
Databases were searched using the rDMGDH cDNA
sequence (Genbank accession number X55995, E.C.
1.5.99.2). The Human Genome Sciences Database was
searched using facilities at SmithKline Beecham. All se-
quencing was performed by the Molecular Biology Core
Sequencing Facility at the Mayo Clinic, using an ABI
Prism model 377 sequencer (Applied Biosystems). PCR
reactions to amplify gaps between ESTs were performed
using PCR Supermix (Gibco BRL). Cycling conditions
were as follows: denaturing at 95C for 3 min; 35 cycles
of denaturing at 94C for 1 min; annealing at 55C for
1 min; extension at 72C for 1 min; extension at 72C
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for 7 min; and soaking at 4C. Human fibroblast cDNA
served as a template. Primers used in the reaction were:
5′-AAGAGATGTTCCCTTTACTC-3′ (forward) and 5′-
TTTAATCTGTTTCAGTGCTTG-3′ (reverse). A PAC
clone containing hDMGDH sequence was obtained
from Genome Systems. PAC DNA was induced to high
copy number and was prepared according to the sup-
plier’s protocol. For direct sequencing of the PAC clone,
DNAwas prepared using kb-100s DNA purification col-
umns (Genome Systems). The rDMGDH primer de-
signed to the sequence of the flavin binding site and used
for indirect PAC clone sequencing was 5′-GTGCCA-
GGTAGAGCCAGCCGTGAGTTCCGA-3′. A second
genomic clone (P1) was also obtained fromGenome Sys-
tems, since the PAC clone was found to be missing at
least one exon at the 5′ end of the gene.
Patient-cDNA/Genomic-DNA Analysis
cDNA was prepared from patient and control fibro-
blast cultures, as described elsewhere (Mohsen et al.
1998). After the H109Rmutation was identified, control
alleles were sequenced around the mutated region. PCR
reactions to amplify the region from cDNA were per-
formed with the following primers: 5′-CAACTTACT-
TTCATCCTGGA-3′ (forward) and 5′-GAGTAAAGG-
GAACATCTCTT-3′ (reverse). PCRwas performed using
the genomic DNA as a template to amplify a region
around the H109Rmutation with the following primers:
5′-TGGCCTCCCCCATAGTTTTA-3′ (forward) and 5′-
GCCTATGGATACTCTTTTGC-3′ (reverse).
Expression of hDMGDH in Mammalian Cells
The precursor sequence for hDMGDH was cloned
into the KpnI site of the pcDNA6/V5-His plasmid
(Invitrogen). Two hundred ninety-three cells (American
Type Culture Collection) were grown in Dulbecco’s min-
imal essential medium supplemented with 10% fetal calf
serum. Cells grown in 6-cm dishes were transfected with
3 mg of either the wild-type or mutant vectors, along
with a pcDNA3.1 His/LacZ control plasmid (Invitro-
gen), using the Calcium Phosphate Transfection kit from
the same company. Forty hours after transfection, the
cells were harvested for western blot analysis or RNA
extraction. Control plates were stained with the b-Gal
staining kit (Invitrogen). For western blots, the isolated
cell pellets were resuspended in PBS, pH 7.4, and were
sonicated briefly; 30 mg of supernatant was loaded onto
a 12% SDS polyacrylamide gel. Western blot analysis
was performed, as described elsewhere, using a 1:1000
dilution of rabbit antiserum, which was raised against
native DMGDH that had been purified from pig liver,
as the primary antibody (Mohsen et al. 1998). To quan-
titate the level of expression of the wild-type and mutant
vectors, mRNAwas extracted from transfected cellswith
the QuickPrepMicromRNAPurification kit (Amersham
Pharmacia Biotech). Then 0.5 mg of RNAwas used, with
the First-Strand cDNA synthesis kit (Amersham Phar-
macia Biotech), to generate first-strand cDNA. One
microliter of the reverse-transcription product was
subjected to PCR with primers specific to DMGDH
(5′-ATGGATTGAAGAAGAAGCAGTC-3′ and 5′-GAT-
GTCGTGTTGCCAACCAC-3′) or b-ETF (5′-CACCC-
TGTAAGTGGCTGC-3′ and 5′-ATGTTGAGAGTCA-
GTTTTATTGCC-3′), with cycling conditions as de-
scribed above. Amplification cycle number was varied
to identify conditions that avoided saturation of the PCR
reaction. PCR products were examined on 1% agarose
gels.
DMGDH Expression Studies.—Mature wild-type rat
and human DMGDH sequences (with amino termini
beginning at Ser22 and Val29, respectively) were sub-
cloned into the pKK223-3 expression vector (Amersham
Pharmacia Biotech) in the EcoRI/HindIII sites. The
H109R mutant, which represents residue 81 in the ma-
ture protein, was created using PCR-based mutagenesis
and was inserted into compatible restriction sites in the
wild-type vectors. Cultures (100 ml) of XL1-Blue cells
containing wild-type, mutant DMGDH, and pKK223-
3 with no insert were grown in 2xYT media plus am-
picillin at 37C, were induced in log-phase growth with
0.05 mM isopropyl-b-D-thiogalactoside, and were al-
lowed to grow overnight at 30C. Cell extracts were
prepared as described elsewhere (Binzak et al. 1998).
Extracts were tested for DMGDH activity using the ETF
reduction assay, as described elsewhere, with 0.5 M di-
methylglycine as substrate (Binzak et al. 1998) (N,N-
dimethylglycine [hydrochloride] was purchased from
Sigma). Protein assays were performed using the Bio-
Rad DC Protein Assay (Bio-Rad). Western blot analysis
was performed as described above.
1HNMR Spectroscopy.—1H NMR spectroscopy of se-
rum and urine specimens was performed essentially as
described elsewhere (Wevers et al. 1994).
Clinical History
The patient is a 38-year-old man of African ancestry
who presented with a fishlike body odor that was first
noticed when he was 5 years old. The intensity of the
odor increases with physiological stress, such as illness,
as well as during times of increased physical activity.
The odor has led to severe psychological problems and
professional difficulties. The patient had normal growth
and development and is of normal intelligence with no
unusual CNS symptoms, but he has experienced chronic
muscular fatigue since adolescence. He has had no
known hematologic problems or liver dysfunction. Rou-
tine clinical chemistry determinations yielded unremark-
able results, with normal levels of cobalamin, folate, and
842 Am. J. Hum. Genet. 68:839–847, 2001
Figure 2 1H NMR spectrum of serum from the DMGDH-
deficient patient. Peaks of relevant metabolites are labeled. The singlet
peak at 2.93 ppm is caused by an accumulation of dimethylglycine in
the patient’s serum.
homocysteine in serum. Creatine kinase levels were con-
sistently found to be four- to fivefold higher than normal
levels. Metabolic investigations—including testing of
amino acids, organic acids, carnitine ester profile, and
serum levels of very-long-chain fatty acids—were nor-
mal. Trimethylaminuria, the only known specific defect
leading to “fish-odor syndrome” was excluded using
NMR spectroscopy of urine (Moolenaar et al. 1999).
The patient does not use any dietary supplements con-
taining either carnitine or dimethylglycine. There is no
known consanguinity in the pedigree, but the patient’s
parents were unavailable for interview. The brothers and
sisters (a precise pedigree was unavailable) and the two
sons of the patient are asymptomatic.
Results
1H NMR
1H NMR spectroscopic analysis of blood samples
from the patient showed a dimethylglycine concentra-
tion of 449 mM creatinine (∼20-fold higher than normal
values) in urine and a concentration of 221 mM/liter
(∼100-fold higher than normal values) in serum. No
other unusual metabolites were present. Figure 2 shows
part of the 1HNMR spectrum of serum from the patient.
A singlet at 2.93 parts per million (ppm) is caused by
dimethylglycine. Dimethylglycine was observed in serum
spectra from healthy individuals only in low concentra-
tion (3.80-ppm singlet; data not shown). The identity of
the dimethylglycine was confirmed using 13C-NMR spec-
troscopy and gas chromatography–mass spectroscopy.
Similar findings had been observed in the patient’s urine
(complete details of biochemical analyses of the urine
have been reported elsewhere [Moolenaar et al. 1999]).
cDNA Cloning
Because of the biochemical findings in this patient, we
suspected a deficiency of DMGDH. To confirm this, we
initiated the cloning of hDMGDH cDNA. The cDNA
sequence for rDMGDH (Lang et al. 1991) was used to
screen several databases to identify a human homologue.
An EST was identified from the Human Genome Sci-
ences database that aligns to the 3′ end of the rat cDNA
and is 92% identical over ∼400 nucleotides. This clone
also contains 1.1 kb of 3′ UTR, including the poly A
tail. A second human EST that aligns near the 5′ end of
the rat cDNA sequence was identified from Genbank.
This EST is 81% identical to the rat sequence over ∼170
nucleotides. PCR was then used to amplify the region
between these two short sequences from human fibro-
blast cDNA made from control fibroblast mRNA. Var-
ious techniques to clone the extreme 5′ end of the cDNA
were unsuccessful; therefore, a human PAC clone was
isolated using ∼1.8 kb of the hDMGDH cDNA as a
probe. Both Southern blot analysis and direct sequencing
of this PAC clone confirm that it contains the hDMGDH
genomic sequence (Binzak et al. 2000). Since the extreme
5′ end of the gene was still missing, a second genomic
clone (P1) was obtained from Genome Systems, and it
proved to contain the final 5′-most exon of coding se-
quence of the gene.
The hDMGDH cDNA is 2,598 nucleotides long,
which suggests the presence of a protein with 866 amino
acids and a 3′ UTR of ∼1,100 nucleotides (fig. 3). Over-
all, the precursor cDNA sequences for hDMGDH and
rDMGDH share 85.6% nucleotide identity, as calcu-
lated using the GAP program from the University of
Wisconsin GCG sequence-analysis software, although
the mature proteins show 91.4% amino acid identity
(93.9% amino acid similarity). The flavin peptide of
rDMGDH (Wittwer and Wagner 1980) is 100% con-
served, at the amino acid level, with the same region
in hDMGDH; however, the area just upstream shows
reduced homology. In fact, the cDNA sequence of
hDMGDH suggests that seven additional amino acids
are present in the mitochondrial targeting peptide, com-
pared with rDMGDH. Val29 is predicted, on the basis
of the known pattern of processing of mitochondrial
leader peptides, to be the amino terminus of the mature
human protein.
Analysis of Patient DNA
Analysis of hDMGDH cDNA and genomic DNA
from the patient identified a homozygous ArG point
mutation at nucleotide 326 of the precursor coding re-
gion (fig. 4). This suggests that the alteration of a His
to an Arg at amino acid 109 (H109R or residue 81 of
the predicted mature protein) occurs 18 amino acids
downstream of the site of the FAD attachment that was
Figure 3 The hDMGDH cDNA sequence. Only the sense strand is shown. Amino acids are represented by their one-letter codes. The
italicized amino acid sequence with a single underline is the putative flavin-binding peptide. The Val residue at position 29 (precursor numbering),
outlined by the triangle, was taken as the mature 5′-end of the cDNA. The boxed His residue is the putative flavin-binding site (corresponding
to His84 in rDMGDH). The circled His residue is mutated in the patient. The underlined nucleotide sequence denotes the probe used to isolate
the hDMGDH PAC clone.
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Figure 4 Patient mutation in the hDMGDH gene. A, Chromatograms of hDMGDH cDNA sequence from a control fibroblast sample
and, B, from a patient fibroblast sample; C, genomic DNA sequence from the patient. mRNA, cDNA, and genomic DNA were prepared as
described in the Patient and Methods section. Sequence shown is read in the 5′r3′ direction. The sequencing primer reads the sequence on the
antisense strand. The arrow indicates the nucleotide that is mutated in the patient: TrC (ArG on sense strand), changing the residue from
CAT (His) to CGT (Arg).
identified for rDMGDH (fig. 3) (Wittwer and Wagner
1981a; Cook et al. 1984). Southern blot analysis of ge-
nomic DNA from patient and control fibroblast DNA
gave an identical pattern, suggesting that no genomic
DNA deletions were present (data not shown). This re-
gion is 100% conserved between rats and humans, and
the alteration was not present in 50 DMGDH alleles
from control human fibroblast samples. The remainder
of the cDNA sequence from the patient matched the
control sequence. No information could be obtained
about nucleotides 1–12, which were contained within
the 5′-most PCR primer; however, this is within the mi-
tochondrial targeting peptide and thus is not represented
in the mature enzyme. Enzymatic assay and western blot
analysis with DMGDH-specific antiserum were not sen-
sitive enough to detect DMGDH, even in control fibro-
blasts. This is in keeping with previous observationswith
this enzyme (Moolenaar et al. 1999). To evaluate the
effect of the H109R substitution on DMGDH enzyme
activity, therefore, the nucleotide 326 ArG mutation
was introduced into hDMGDH cDNA, and both the
normal and mutant sequences were expressed in Es-
cherichia coli, Saccharomyces cerevisiae, and a variety
of mammalian tissue culture samples. No active enzyme
could be detected in E. coli after expression of the nor-
mal hDMGDH, although immunoreactive material was
present (data not shown). Similarly, expression studies
in yeast yielded no hDMGDH antigen. After expression
of the wild-type cDNA in 293 cells, DMGDH antigen
could be detected, although the level of expression was
not high enough to allow measurement of enzyme ac-
tivity (fig. 5A). When a cDNA containing the patient
mutation was similarly expressed, hDMGDH antigen
was barely detectable (fig. 5A), although the transfection
efficiency was similar for both vectors, as determined by
b-galactosidase staining of colonies on the transfection
plates (data not shown). The levels of DMGDH-specific
mRNA after transfection with the wild-type and mutant
plasmids, as determined by a semiquantitative PCR tech-
nique (fig. 5B), were much lower in themock-transfected
cells. In contrast, b-ETF–specific primers used as a con-
trol showed a similar level of this message in all samples
(fig. 5C).
Because the region containing the patient mutation is
identical in rat and human genes, the mutation was in-
troduced into rDMGDH in a prokaryotic expression
vector previously made in our laboratory, and the wild-
type and mutant proteins produced in E. coli were char-
acterized. After overnight induction of a culture con-
taining the wild-type vector, DMGDHmean SD
activity in cellular extracts was mU/mg pro-0.14 0.03
tein ( ) (as measured with the anaerobic electronnp 9
transferring flavoprotein assay), although no activity
was detectable in extracts from cells containing a vector
with the mutant rDMGDH cDNA or a vector with no
insert (!10% control activity). In contrast, western blot
analysis of the cellular extracts shows that levels of wild-
type and mutant protein were similar after induction,
indicating that the mutant enzyme was stable but in-
active (fig. 6).
Discussion
Our findings unequivocally identify a deficiency of
DMGDH as the cause of accumulation of dimethylgly-
cine in the urine and serum of this patient. The accu-
mulation appears to be the result of a homozygous point
mutation in the DMGDH gene, although the presence
of a large deletion on one allele at this locus, leading to
hemizygosity for the point mutation cannot be excluded.
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Figure 5 Expression of wild-type and mutant hDMGDH in 293
cells. A, Western blot analysis of cellular extracts after SDS-PAGE.
Lanes 1 and 2, extracts from cells transfected in separate experiments
with wild-type hDMGDH vector; lanes 3 and 4, extracts from cells
transfected in separate experiments with an hDMGDH vector con-
taining the patient mutation; lane 5, mock transfection; lane 6, partially
purified pig liver DMGDH. B, RT-PCR results in transfected cells.
Lanes 1 and 2, cells transfected with wild-typeDMGDH vector; lanes
3 and 4, cells transfected with an hDMGDH vector containing the
patient mutation; lanes 5 and 6, mock transfection. Lanes 1, 3, and
5 are products after 16 cycles of amplification. Lanes 2, 4, and 6 are
products after 18 cycles of amplification. C, b-ETF message in samples
prepared concurrently with those shown in panel B. Lanes 1–3, cells
transfected with wild-type DMGDH vector; lanes 4–6, cells trans-
fected with an hDMGDH vector containing the patientmutation; lanes
7–9 mock transfection. Lanes 1, 4, and 7 are products after 20 cycles
of amplification. Lanes 2, 5, and 8 are products after 22 cycles of
amplification. Lanes 3, 6, and 9 are products after 24 cycles of
amplification.
Figure 6 Western blot of wild-type and mutant rDMGDH pro-
duced in E. coli. DMGDH purified from pig liver for reference (lane
1). Extracts from induced cells containing the wild-type rDMGDH
vector (lane 2) and rDMGDH containing the patient mutation (lane
3) were separated by SDS-PAGE, were transferred to a polyvinyldiene
fluoride membrane, and were examined using anti-DMGDH antibod-
ies. No DMGDH-specific band was present in extracts from cells con-
taining no plasmid or plasmid without insert (data not shown).
Although the level of expression of the wild-type and
mutant cDNAs in a eukaryotic expression system was
too low to allow direct measurement of enzyme activity,
the level of mutant enzyme antigen was clearly lower
than that of the wild-type enzyme antigen, most likely
indicating reduced stability of the mutant protein. This
is consistent with the E. coli expression data for the
mutant enzyme, because it was unstable in this system.
Additional prokaryotic expression studies confirm that
the point mutation inactivates enzymes when introduced
into the rat coding sequence, which is 100% conserved
in this region of the human enzyme. Thus, even if a
mutant human enzyme were stably formed in the cell,
it would not be active.
In view of the potential consequence of a disruption
of metabolism of methyl groups related to DMGDH
action, which are necessary for several other important
cellular reactions, this patient’s clinical symptoms are
surprisingly mild. Clearly, other sources of methyl
groups for these reactions must be available when
DMGDH is deficient. Because sarcosine in DMGDH
deficiency can still be produced directly from glycine via
glycine methyltransferase, which uses S-adenosylme-
thionine as a methyl donor, the remainder of the down-
stream reactions of choline catabolism can likely still
proceed to some extent; however, chronic elevation
of serum creatine kinase levels in this patient are indica-
tive of ongoing muscle breakdown, suggesting that
DMGDH deficiency does have physiologic repercus-
sions.
The HisrArg mutation demonstrated in the patient’s
DMGDH enzyme is in close proximity to the predicted
FAD attachment site and could lead to a disruption of
flavin binding. Alternatively, the mutation may disrupt
interaction with folate. It has not been definitively de-
termined where folate associates with the enzyme, but
a compelling case has been made for association near
the amino terminus of the protein based on structural
information available for another folate-dependent en-
zyme, thymidylate synthase. The region starting 10
amino acids toward the C-terminus from the His91
(precursor numbering) flavin-binding site in DMGDH
contains 3 Lys residues conserved in both the human
and rat enzyme (residues 106, 107, and 114 in the pre-
cursor) and is homologous to a highly conserved motif
present in several thymidylate synthase enzymes from
various sources (Maley et al. 1982; Hardy et al. 1987;
Lang et al. 1991). A thymidylate synthase has been crys-
tallized from Lactobacillus casei, and the Lys residues
in this region are important in binding its folate coen-
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zyme, H4PteGlu7 (Hardy et al. 1987). It is important to
note that, in the patient described here, the H109R mu-
tation lies between these Lys residues and may lead to
disruption of folate binding in the mutant DMGDH
enzyme. However, these Lys residues are not conserved
in the evolutionarily related SDH, suggesting that
DMGDH and SDH may have a different mechanism of
association with their folate coenzyme (Bergeron et al.
1998). Alternatively, some other binding motif may be
responsible for folate association. The presence of a
Lys/Arg–rich region between Lys740 and Arg764 in
rDMGDH has also been implicated in folate binding
(Otto et al. 1996). This region is similarly Lys/Arg rich
in hSDH and hDMGDH (Bergeron et al. 1998).
Here we present the cloning of the cDNA for
hDMGDH and the identification of a homozygous
H109Rmutation in a patient presenting with a fish odor
and having high dimethylglycine levels in his serum and
urine. In conjunction with our previous report (Mool-
enaar et al. 1999), this confirms that this patient rep-
resents the first identified case of DMGDH deficiency,
a new inborn error of metabolism.
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